Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers
- 1 July 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (7), 3081-3087
- https://doi.org/10.1128/aac.01661-08
Abstract
Shiga toxin (Stx)-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic-uremic syndrome (HUS). The rates of STEC infection and complications, including death, are highest among young children and elderly individuals. There are no causal therapies. Because Stx is the primary pathological agent leading to organ injury in patients with STEC disease, therapeutic antibodies are being developed to neutralize systemically absorbed toxin during the early phase of the infection. Two phase I, single-dose, open-label, nonrandomized studies were conducted to evaluate the safety and pharmacokinetics of the chimeric monoclonal antibodies (antitoxins) against Stx 1 and 2 (cαStx1 and cαStx2, respectively). In the first study, 16 volunteers received 1 or 3 mg/kg of body weight of cαStx1 or cαStx2 as a single, short (1-h) intravenous infusion ( n = 4 per group). In a second study, 10 volunteers received a 1-h infusion of cαStx1 and cαStx2 combined at 1 or 3 mg/kg ( n = 5 per group). Treatment-emergent adverse events were mild, resolved spontaneously, and were generally unrelated to the antibody infusion. No serious adverse events were observed. Human antichimeric antibodies were detected in a single blood sample collected on day 57. Antibody clearance was slightly greater for cαStx1 (0.38 ± 0.16 ml/h/kg [mean ± standard deviation]) than for cαStx2 (0.20 ± 0.07 ml/h/kg) ( P = 0.0013, t test). The low clearance is consistent with the long elimination half-lives of cαStx1 (190.4 ± 140.2 h) and cαStx2 (260.6 ± 112.4 h; P = 0.151). The small volume of distribution (0.08 ± 0.05 liter/kg, combined data) indicates that the antibodies are retained within the circulation. The conclusion is that cαStx1 and cαStx2, given as individual or combined short intravenous infusions, are well tolerated. These results form the basis for future safety and efficacy trials with patients with STEC infections to ameliorate or prevent HUS and other complications.Keywords
This publication has 24 references indexed in Scilit:
- Treatment options for HUS secondary to Escherichia coli O157:H7Kidney International, 2009
- Mouse Model of Hemolytic-Uremic Syndrome Caused by Endotoxin-Free Shiga Toxin 2 (Stx2) and Protection from Lethal Outcome by Anti-Stx2 AntibodyInfection and Immunity, 2008
- Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaksProceedings of the National Academy of Sciences of the United States of America, 2008
- Characterisation of Shiga toxin-producing Escherichia coliO157 strains isolated from humans in Argentina, Australia and New ZealandBMC Microbiology, 2008
- Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157European Journal of Clinical Microbiology & Infectious Diseases, 2007
- The 13C4 Monoclonal Antibody That Neutralizes Shiga Toxin Type 1 (Stx1) Recognizes Three Regions on the Stx1 B Subunit and Prevents Stx1 from Binding to Its Eukaryotic Receptor GlobotriaosylceramideInfection and Immunity, 2006
- Phase 1 Safety and Pharmacokinetic Study of Chimeric Murine-Human Monoclonal Antibody cαStx2 Administered Intravenously to Healthy Adult VolunteersAntimicrobial Agents and Chemotherapy, 2005
- Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic SyndromeClinical Microbiology Reviews, 2004
- Escherichia coliHarboring Shiga Toxin 2 Gene Variants: Frequency and Association with Clinical SymptomsThe Journal of Infectious Diseases, 2002
- A Severe Outbreak ofEscherichia coliO157:H7–Associated Hemorrhagic Colitis in a Nursing HomeNew England Journal of Medicine, 1987